Ultragenyx Pharmaceutical | RARE - Zinsaufwendungen Für Schuld

Aktienkurs
19.87
Täglich Wechseln
-0.55 -2.69%
Monatlich
-11.73%
Jährlich
-49.29%
Q1 Prognose
19.27




Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Esperion Therapeutics USD 22.64M 585K 2025-12
Immunic 400K 400K 2024-12
Insmed USD 20.6M 217K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
Karyopharm Therapeutics USD 11.38M 2.43M 2024-09
Kyowa Hakko Kirin JPY 435M 94M 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
Moderna USD 12.14B 12.13B 2025-09
Neurocrine Biosciences USD 1.1M 0 2024-03
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xoma USD 3.4M 150K 2024-06